- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06333795
Faecal Microbiota Transplantation Against Chronic Diarrhea in Patients With Systemic Sclerosis (FaeMiCue)
Faecal Microbiota Transplantation Against Chronic Diarrhea in Patients With Systemic Sclerosis - a Randomized, Double-blinded, Safety and Pilot-efficacy Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The present study aims to assess the feasibility, pilot efficacy, and safety of FMT for patients with Systemic Sclerosis.
Participants will undergo two interventions in this present study.
In the first intervention, participants are randomized 1:1 for either active FMT or Placebo. This first intervention consists of two doses of FMT with a 3-7 day gap.
In the second intervention, all participants receive 1 dose of active FMT treatment.
This study design allows researchers to evaluate the safety of FMT in this patient group, and compare the effects of FMT in the FMT-treated group vs the placebo group, to see if FMT promotes remission of Chronic diarrhea. Furthermore, researchers will be able to gain insights into whether 2 initial doses are superior to one.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nanna S Rolighed, PhD-student
- Phone Number: 52199715
- Email: Nanna.rolighed@clin.au.dk
Study Contact Backup
- Name: Klaus Krogh, MD, DMSc
- Phone Number: 23385937
- Email: klaukrog@rm.dk
Study Locations
-
-
-
Aarhus, Denmark
- Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants > 18 years
- Fulfilling and previously diagnosed with SSc according to the 2013 American College of Rheumatology/European League against rheumatisms SSs classification criteria[23] by rheumatologist or dermatologist.
- Chronic diarrea is defined as loose or watery stools, three or more times a day, a minimum of 50% of the days within the last four weeks.
Exclusion Criteria:
- Inability to understand Danish spoken or written and/or Trial procedures.
- Known or anticipated pregnancy (excluded by male sex, postmenopausal women, or otherwise negative U-HCG)
- Previous treatment with FMT
- Treatment with antibiotics within the past 6 weeks
- Changes in morphine treatment within the past 4 weeks
- Ongoing infection with Clostridioides difficile (negative PCR test)
- Known serious gastrointestinal disease or GI infection (diagnosed with e.g. inflammatory bowel disease and/or gastrointestinal cancer)
- Dysregulated thyroid disease (TSH) blood sample from previous consultations maximum 6 months old from
- Known intestinal stricture
- Planned MR scan within the study period
- Pacemaker/ICD
- Previous abdominal surgery (minor surgical procedures ex. appendectomy is allowed)
- Changes in medicine that affect the GI tract within the past four weeks.
Known Severe end-organ disease
- Lung disease with forced vital capacity(FVC)<50% and/or diffusing lung capacity for carbon monoxide (DLCO) <40%
- Severe heart failure with ejection fraction <30%
- End-stage kidney disease with glomeration rate<30ml/min
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active treatment
Active capsule FMT-treatment
|
Treatment is given as capsules.
|
Placebo Comparator: Placebo
Placebo capsules are given.
|
Treatment is given as capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events (AE) severity grade 2 or more assessed by CTCAE v5.0. during the first week after intervention (FMT or placebo).
Time Frame: The first week after treatment.
|
Patient-reported measures from the schedule of side effects and telephone call 1 week after each intervention.
|
The first week after treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-reported treatment outcome on symptoms
Time Frame: The first week after treatment.
|
Based on self-reported data from the bowel habit diary.
|
The first week after treatment.
|
Patient-reported measures from the schedule of side effects and telephone call 1 week after each intervention.
Time Frame: One week after each treatment
|
Mild adverse events (grade 1) following FMT or placebo assessed by (Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0) CTCAE v5.0. The CTCAE grades adverse events (AEs) based on severity: Grade 1: Mild, asymptomatic, or mild symptoms; no intervention needed. Grade 2: Moderate; requires minimal intervention; affects age-appropriate activities. Grade 3: Severe or medically significant, not immediately life-threatening; may require hospitalization. Grade 4: Life-threatening; urgent intervention needed. Grade 5: AE-related death. Note: Some AEs may not have all five grades available. |
One week after each treatment
|
Patient-reported outcomes from questionnaires.
Time Frame: At Baseline and 4 weeks after Intervention 1 & 2
|
Change in Gastrointestinal syndrome rating scale - irritable bowel version questionnaire (GSRS-IBS)
|
At Baseline and 4 weeks after Intervention 1 & 2
|
Patient-reported outcomes from questionnaires.
Time Frame: At Baseline and 4 weeks after Intervention 1 & 2
|
Change in Wexner incontinence score.
|
At Baseline and 4 weeks after Intervention 1 & 2
|
Patient-reported outcomes from questionnaires.
Time Frame: At Baseline and 4 weeks after Intervention 1 & 2
|
Change in UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0)
|
At Baseline and 4 weeks after Intervention 1 & 2
|
Patient-reported overall symptom burden
Time Frame: Each week for a total of 26 weeks.
|
The patients self-reported the severity of symptoms and their impact on daily life each week on a scale from 1-5. 1 being little to no burden, 5 being most severe.
|
Each week for a total of 26 weeks.
|
Objective measures from the wireless motility capsule.
Time Frame: At baseline
|
Transit time through the small intestine.
|
At baseline
|
Objective measures from the wireless motility capsule.
Time Frame: At baseline
|
Colonic transit times
|
At baseline
|
Objective measures from the wireless motility capsule.
Time Frame: At baseline
|
Total gastrointestinal transittimes
|
At baseline
|
Objective measures from the wireless motility capsule.
Time Frame: At baseline
|
Ph drop from the small intestine to the colon
|
At baseline
|
Objective measures from the low-dose CT scan.
Time Frame: At baseline and 4 weeks after first intervention
|
Volume of the a) small intestine and b) the colon. Volume of gas in a) the small intestine and b) the colon. Changes in the gas volume in the small intestine and colon. |
At baseline and 4 weeks after first intervention
|
Breath Test
Time Frame: At baseline and 4 weeks after first intervention
|
Changes in the rise of hydrogen and methane measured in breath test
|
At baseline and 4 weeks after first intervention
|
Faecal microbiota composition
Time Frame: At baseline and between each treatment, up to 4 weeks after last intervention
|
Changes in faecal microbiome composition.
Alfa and beta diversity determined by sequencing of the intestinal microbiome.
|
At baseline and between each treatment, up to 4 weeks after last intervention
|
Faecal-calprotectin
Time Frame: At Baseline and 4 weeks after Intervention 1 & 2
|
Percentual change in faecal-calprotectin from before intervention to 4 weeks after each intervention.
|
At Baseline and 4 weeks after Intervention 1 & 2
|
Blood plasma proteomics
Time Frame: At baseline and between each treatment, up to four weeks after last intervention.
|
Changes in blood immunological parameters (including proteins) from baseline and between each treatment, at 4 weeks after intervention.
|
At baseline and between each treatment, up to four weeks after last intervention.
|
Blood plasma Fibrosis markers
Time Frame: At baseline and between each treatment, up to four weeks after last intervention.
|
Changes in blood immunological parameters (including markers of fibrosis) from baseline and between each treatment, at 4 weeks after intervention.
|
At baseline and between each treatment, up to four weeks after last intervention.
|
Blood parameters
Time Frame: At baseline and between each treatment, up to four weeks after last intervention.
|
Changes in blood immunological parameters (including circulating cytokines) from baseline and between each treatment, at 4 weeks after intervention.
|
At baseline and between each treatment, up to four weeks after last intervention.
|
Health-related Quality of life
Time Frame: At baseline and 4 weeks after Intervention 1 & 2
|
Changes in Health-related Quality of life assessed with (EQ-5D-5L). Each of the five dimensions comprising the EQ-5D descriptive system is divided into five levels of perceived problems: LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/Extreme problems An EQ-VAS from 0-100 is added, 100 being the best possible health. |
At baseline and 4 weeks after Intervention 1 & 2
|
Patient perception of FMT treatment satisfaction
Time Frame: At 4 weeks after interventions 1 & 2
|
Patient perception of FMT treatment satisfaction was assessed by 7-point Likert scale for patients.
1: no benefits from treatment to 7 being very satisfied with treatment.
|
At 4 weeks after interventions 1 & 2
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-10-72-131-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diarrhea
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
-
Napo Pharmaceuticals, Inc.Active, not recruitingAdult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related DiarrheaUnited States, Taiwan, Georgia, Serbia, Argentina
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Hospital San BartolomeInstituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo...Unknown
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Sana'a UniversityCompleted
-
PATHUniversity of Maryland; Center for Vaccine Development - MaliCompleted
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Augusta UniversityNRS Medical College, Kolkata, West Bengal, India; School of Tropical Medicine...Terminated
Clinical Trials on Faecal Microbiota Transplantation (FMT)
-
St Vincent's Hospital MelbourneUnknownCrohn Disease | Ulcerative Colitis | Microscopic Colitis | Faecal Microbiota TransplantationAustralia
-
University of AarhusRecruitingKidney Cancer | Diarrhea | Colitis | Malignant MelanomaDenmark
-
University of AarhusRecruitingClostridium Difficile InfectionDenmark
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruiting
-
Odense University HospitalUniversity of Southern Denmark; Region of Southern DenmarkRecruitingRheumatoid Arthritis | Crohn Disease | Ulcerative Colitis | Psoriatic Arthritis | Ankylosing Spondylitis | Pulmonary SarcoidosisDenmark
-
University of AarhusCompletedDiabetes Mellitus, Type 1 | Faecal Microbiota Transplantation (FMT) | Gastrointestinal NeuropathyDenmark
-
Örebro University, SwedenRegion Örebro CountyCompleted
-
Chinese University of Hong KongActive, not recruiting
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Jena University HospitalGerman Federal Ministry of Education and ResearchNot yet recruitingInflammatory Bowel Diseases | Ulcerative Colitis